Chronic myeloid leukemia (CML) accounts for 2‐3% of leukemias in children under 15 and
9% in adolescents aged 15‐19. The diagnosis and management of CML in children …

With survival expectation that of age-matched controls and given excellent response and
worldwide access to tyrosine kinase inhibitors (TKI), family planning is increasingly …

Several papers authored by international experts have proposed recommendations on the
management of BCR-ABL1+ chronic myeloid leukemia (CML). Following these …

1St James's University Hospital, Leeds, 2Imperial College, London, 3University of
Southampton, Southampton, 4University Hospital, Nottingham, 5University Hospital of …

Purpose To review the impact of tyrosine kinase inhibitors (TKIs) on fertility in men and
women, embryo development, and early pregnancy, and discuss considerations for fertility …

Clinical trials have formally demonstrated that in chronic myeloid leukemia (CML), patients
treated with tyrosine kinase inhibitors (TKI) who achieved and maintained deep molecular …

Abstract Purpose of Review Tyrosine kinase inhibitors (TKIs) allow many patients with
chronic myeloid leukemia (CML) to live normal life spans but have the potential to impact …

Adequate information on oral anticancer agent (OACA) use is an essential element of
optimal cancer care. The present study aimed to get insight into the experiences of patients …

Both favorable pregnancy outcomes and fetal abnormalities have been associated with the
use of tyrosine kinase inhibitors (TKIs) during pregnancy. The placental transfer of TKIs in …

Background Imatinib is a first-line tyrosine kinase inhibitor for treating chronic myelogenous
leukaemia (CML) and has greatly improved the prognosis of this disease. An increasing …